Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.

Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.

Alan L. Ho, MD, PhD, discusses the unique elements of Oz-V that may contribute to its efficacy and tolerability in OPSCC.

Roisin E. O'Cearbhaill, MD, discusses a phase 1/2 trial assessing REGN5668 combined with other targeted agents in recurrent endometrial or ovarian cancer.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.

Jae Park, MD, discusses the importance and utility of MRD testing in the current acute lymphoblastic leukemia management field.

Jae Park, MD, discusses obe-cel in relapsed or refractory acute lymphoblastic leukemia and how new data are helping to shape its role.

Jae Park, MD, discusses recent developments for obe-cel and brexu-cel in acute lymphoblastic leukemia.

Lillian Rodich, MSPAS, MPH, highlights ways that medical oncologists can counsel patients with breast cancer about integrative medicine modalities.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Dr Schrag weighed in on where oncology stands today and previewed the goals she hopes to advance during her tenure as ASCO President in 2027-2028.

Dr Jhaveri discusses the evaluation of sacituzumab govitecan earlier in the HR-positive, HER2-negative metastatic breast cancer treatment paradigm.

Komal Jhaveri, MD, FACP, discusses lessons learned from the negative phase 3 ASCENT-07 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr Falchi discusses why the FDA approval of epcoritamab plus lenalidomide/rituximab is clinically meaningful for relapsed/refractory follicular lymphoma.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Saad Z. Usmani, MD, MBA, FACP, FASCO, is renowned leader whose work has helped redefine treatment standards and extend the lives of patients worldwide.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

Kenneth Offit, MD, MPH, is a pioneering cancer geneticist whose groundbreaking work has shaped how hereditary cancer is understood, prevented, and managed.

David G. Pfister, MD, developed a combined modality organ preservation treatment program that shifted the landscape of head and neck cancers.

Passion to help individual patients fueled the career of Mark G. Kris, MD, in driving lung cancer research and management.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib as a targeted therapy for relapsed/refractory, NPM1-mutant AML.

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.